Evidence map›Paper›PMID 33533976›Full record

ArticleArchives of virology2021

Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.

Mohamed Darwish Ahmed Abd Alla, Reham M Dawood, Hassan Abd El-Hafeth Rashed, Galal Farrag, Islam Abdelmawla Emran Ammar, Mohamed Mahmoud Abdel-Halim Mahmoud, Ghada M Salum, Ahmed Mohamed Abdulhamid Altanbouly, Mai A El Meguid, Mostafa K El Awady

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Mohamed Darwish Ahmed Abd AllaDepartment of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt. darwish0716@azhar.edu.eg.ORCID http://orcid.org/0000-0002-3601-6907
Reham M DawoodDepartment of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Hassan Abd El-Hafeth RashedDepartment of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Galal FarragDepartment of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Islam Abdelmawla Emran AmmarDepartment of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Mohamed Mahmoud Abdel-Halim MahmoudDepartment of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Ghada M SalumDepartment of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Ahmed Mohamed Abdulhamid AltanboulyDepartment of Hepatology, Gastroenterology and Infectious Diseases, Faculty of Medicine, El-Hussein University Hospital, Al-Azhar University, Gouhar Al-Kaed Street, Al-Darasah, Cairo, 11675, Egypt.
Mai A El MeguidDepartment of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Mostafa K El AwadyDepartment of Microbial Biotechnology, National Research Center, Cairo, Egypt.
Al-Azhar University · EGNational Water Research Center · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elimination of hepatitis C virus (HCV) may fail, leading to a non-response outcome because of inappropriate testing for viral RNA in peripheral blood mononuclear cells (PBMCs). Sequelae of HCV genotype 4 therapy with sofosbuvir and daclatasvir ± ribavirin were assessed in our study at the 12

Indexed as

AdultAntiviral AgentsCarbamatesDrug Therapy, CombinationFemaleHepacivirusHepatitis C, ChronicHumansImidazolesLeukocytes, MononuclearLiverMaleMiddle AgedParenchymal TissuePyrrolidinesRibavirinAntiviral AgentsCarbamatesdaclatasvirImidazolesPyrrolidinesRibavirinRNA, ViralSofosbuvirValine

Identifiers

PMID33533976
OpenAlexW3127678231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.